RT Journal
A1 Huesch M, Lakdawalla D
T1 Freedom to innovate: The perils of centralized medical research
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2012
FD November 26
VO 172
IS 21
SP 1692
OP 1693
DO 10.1001/2013.jamainternmed.53
UL http://dx.doi.org/10.1001/2013.jamainternmed.53
AB 
Prasad and colleagues1 present a viewpoint on the evolution of medical practices, with a striking claim and a problematic recommendation. They claim that there is “no incentive for companies to test scientific questions, which may only diminish market demand.”1(p957) Their proffered solution is that “trial funding should move away from industry-sponsored studies and toward a model where funds are pooled into a central and impartial agency that decides what trials to administer.”1(p957)